Trilaciclib (G1T28)
This product is for research use only, not for human use. We do not sell to patients.
For small sizes, please check our retail website as below: www.invivochem.com
| Size | Price | Stock |
|---|---|---|
| 100mg | $750 | Check With Us |
| 250mg | $1450 | Check With Us |
| 500mg | $2175 | Check With Us |
: Cat #: V16810 CAS #: 1374743-00-6 Purity ≥ 98%
Description: Trilaciclib (G-1T28; G1T28; Cosela) is a novel, first-in-class and short-acting CDK4/6 inhibitor approved in 2021 by FDA as a medication to reduce the frequency of chemotherapy-induced bone marrow suppression.
Top Publications Citing Invivochem Products
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 446.55 |
|---|---|
| Molecular Formula | C24H30N8O |
| CAS No. | 1374743-00-6 |
| Protocol | In Vitro | Incubation with Trilaciclib (G1T28) for 24 h induces intense G1 Cell cycle arrest (time = 0). 16 h after Trilaciclib clearance, cells have re-entered the cell cycle and exhibit cell cycle dynamics similar to untreated control cells. These results suggest that Trilaciclib causes a short-lived, reversible G1 Stagnant. Trilaciclib-mediated transient G in CDK4/6 sensitive cells1 Cell cycle arrest reduces the in vitro toxicity of a variety of commonly used cytotoxic chemotherapy drugs associated with myelosuppression |
|---|---|---|
| In Vivo | Trilaciclib (G1T28) treatment produces strong dose-dependent inhibition of proliferation of HSPC within 12 hours, and EdU incorporation returns to near-baseline levels in a dose-dependent manner within 24 hours of dosing. These data suggest that a single oral dose of Trilaciclib can produce reversible cell cycle arrest in HSPC in a dose-dependent manner in vivo. Mice given 30 mg/kg Trilaciclib 100 min prior to etoposide treatment showed only caspase-3/7 activity at background levels. These data suggest that Trilaciclib can protect bone marrow in vivo from chemotherapy-induced apoptosis. Data suggest that treatment with Trilaciclib prior to 5-FU may reduce chemotherapy-induced 5-FU injury in HSPC, thereby accelerating recovery of blood counts after chemotherapy |
These protocols are for reference only. InvivoChem does not
independently validate these methods.
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 2.2394 mL | 11.1970 mL | 22.3939 mL | 44.7878 mL |
| 5mM | 0.4479 mL | 2.2394 mL | 4.4788 mL | 8.9576 mL |
| 10mM | 0.2239 mL | 1.1197 mL | 2.2394 mL | 4.4788 mL |
| 20mM | 0.1120 mL | 0.5598 mL | 1.1197 mL | 2.2394 mL |
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
=
Concentration
×
Volume
×
Molecular Weight*
The dilution calculator equation
Concentration(start)
×
Volume(start)
=
Concentration(final)
×
Volume(final)
This equation is commonly abbreviated as: C1 V1 = C2 V2
Concentration(start)
C1
×
Volume(start)
V1
=
Concentration(final)
C2
×
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg
Average weight of animals g
Dosing volume per animal µL
Number of animals
Step Two: Enter the in vivo formulation
%DMSO
+
%
+
%Tween 80
+
%ddH2O
Calculation Results:
Working concentration:
mg/ml;
Method for preparing DMSO master liquid:
mg
drug pre-dissolved in
µL
DMSO(Master liquid concentration
mg/mL)
,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:
Take
µL
DMSO master liquid, next add
µL
PEG300, mix and clarify, next add
µL
Tween 80,mix and clarify, next add
µL
ddH2O,mix and clarify.
Note:
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.